Vadimezan (DMXAA), 25mg

Vadimezan (DMXAA) is a vascular disrupting agents (VDA)and competitive inhibitor of DT-diaphorasewith Ki of 20 μM and IC50 of 62.5 μM in cell-free assays, respectively. DMXAA (Vadimezan) is also a STINGagonist with potential antineoplastic activity. DMXAA (Vadimezan) potently induces IFN-βbut relatively low TNF-αexpression in vitro. DMXAA (Vadimezan) has antiviral activity. Phase 3.